A potent and orally efficacious, hydroxyethylamine-based inhibitor of β-Secretase

ACS Medicinal Chemistry Letters

Volumn 3, Issue 11, 2012, Pages 886-891

  Kaller, Matthew R ^a   Harried, Scott S ^a   Albrecht, Brian ^a,b   Amarante, Patricia ^a   Babu Khan, Safura ^a   Bartberger, Michael D ^a   Brown, James ^a   Brown, Ryan ^a   Chen, Kui ^a   Cheng, Yuan ^a   Citron, Martin ^a,f   Croghan, Michael D ^a   Graceffa, Russell ^a   Hickman, Dean ^a   Judd, Ted ^a   Kriemen, Chuck ^a   La, Daniel ^a   Li, Vivian ^a   Lopez, Patricia ^a   Luo, Yi ^a   Masse, Craig ^a,c   Monenschein, Holger ^d   Nguyen, Thomas ^a   Pennington, Lewis D ^a   Miguel, Tisha San ^a   Sickmier, E Allen ^a   Wahl, Robert C ^a   Weiss, Matthew M ^a   Wen, Paul H ^a   Williamson, Toni ^a   Wood, Stephen ^a   Xue, May ^a   Yang, Bryant ^a   Zhang, Jianhua ^a   Patel, Vinod ^a,e   Zhong, Wenge ^a   Hitchcock, Stephen ^a,d   more..

^a AMGEN INC   (United States)

^b Department of Structural Biology   (United States)

^c Nimbus Discovery   (United States)

^d Envoy Therapeutics   (United States)

^e Sanofi Aventis   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

amyloid precursor protein cleaving enzyme (BACE); Alzheimer's disease (AD); hydroxyethylamine (HEA) isostere

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; BETA SECRETASE INHIBITOR; ETHYLAMINE; HYDROXYETHYLAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RAT;

EID: 84867590209     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml3000148     Document Type: Article

References (17)

1. http://www.alz.org/documents-custom/report-alzfactsfigures2010.pdf.
2. Vassar, R.; Bennett, B. D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E. A.; Denis, P.; Teplow, D. B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M. A.; Biere, A. L.; Curran, E.; Burgess, T.; Louis, J. C.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE Science 1999, 286, 735-741
3. Hardy, J.; Selkoe, D. J. The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics Science 2002, 297, 353-356
4. Tanzi, R. E.; Bertram, L. Twenty Years of the Alzheimer's Disease Amyloid Hypothesis: A Genetic Perspective Cell 2005, 120, 545-555
5. De Strooper, B.; Vasar, R.; Golde, T The secretases: Enzymes with therapeutic potential in Alzheimer's disease Nature Rev. Neurol. 2010, 6, 99-107
6. Silvestri, R. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease Med. Res. Rev. 2008, 29, 295-338
7. Stachel, S. J. Progress toward the development of a viable BACE-1 inhibitor Drug Dev. Res. 2009, 70, 101-110
8. Lopez, P.; Zhong, W.; Albrecht, B.; Amarante, P.; Andersen, D.; Babu-Khan, S.; Bartberger, M. D.; Brown, J.; Chen, K.; Cheng, Y.; Citron, M.; Croghan, M. D.; Graceffa, R.; Harried, S. S.; Hickman, D.; Hungate, R.; Jordan, S.; Kaller, M. R.; Kriemen, C.; La, D.; Luo, Y.; San Miguel, T.; Monenschein, H.; Nguyen, T.; Nixey, T.; Pennington, L. D.; Wahl, R. C.; Weiss, M. M.; Wood, S.; Xue, M.; Yang, B.; Yan, Q.; Zhang, J; Zhang, J.; Patel, V.; Hitchcock, S. Optimization of P1' Interactions in a Series of Hydroxyethylamine Derived Small Molecule BACE1 Inhibitors. Manuscript in preparation.
9. Lanz, T. A.; Himes, C. S.; Pallante, G.; Adams, L.; Yamazaki, S.; Amore, B.; Merchant, K. M. The γ-secretase inhibitor N -[ N -(3,5- difluorophenacetyl)-L-alanyl]- S -phenylglycine t -butyl ester reduces Abeta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice J. Pharmacol. Exp. Ther. 2003, 305, 864-871
10. Reynolds, C. H.; Tounge, B. A.; Bembenek, S. D. Ligand Binding Efficiency: Trends, Physical Basis, and Implications J. Med. Chem. 2008, 51, 2432-2438 and references therein
11. Hitchcock, S. A.; Pennington, L. D. Structure-Brain Exposure Relationships J. Med. Chem. 2006, 49, 7559-7583
12. Maillard, M.; Baldwin, E. T.; Beck, J. T.; Hughes, R. T.; Varghese, J.; Pulley, S. R.; Tenbrink, R. Acetyl 2-Hydroxy-1,3-diaminoalkanes. PCT Int. Appl. WO 2004024081, 2004.
13. Ellman, J. A.; Owens, T. D.; Tang, T. P. N-tert -Butanesulfinyl Imines: Versatile Intermediates for the Asymmetric Synthesis of Amines Acc. Chem. Res. 2002, 35, 984-995
14. Parkes, K. E. B.; Bushnell, D. J.; Crackett, P. H.; Dunsdon, S. J.; Freeman, A. C.; Gunn, M. P.; Hopkins, R. A.; Lambert, R. W.; Martin, J. A.; Merret, J. H.; Redshaw, S.; Spurden, W. C.; Thomas, G. J. Studies toward the large-scale synthesis of the HIV proteinase inhibitor Ro 31-8959 J. Org. Chem. 1994, 59, 3656-3664
15. Harried, S. S.; Croghan, M. D.; Kaller, M. R.; Lopez, P.; Zhong, W.; Hungate, R.; Reider, P. J. Stereoselective Synthesis of anti-N-Protected 3-Amino-1,2-epoxides by Nucleophilic Addition to N-tert-Butanesulfinyl Imine of a Glyceraldehyde Synthon J. Org. Chem. 2009, 74, 5975-5982
16. Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures J. Org. Chem. 1996, 61, 3849-3862
17. Example 7-B [(S)-2-hydroxy-3-methyl- N -((S)-1-(((S)-5-methyl-6-oxo-6,7- dihydro-5 H -dibenzo[ b, d ]azepin-7-yl)amino)-1-oxopropan-2-yl)butanamide]. Wu, J.; Tung, J. S.; Thorsett, E. D.; Pleiss, M. A.; Nissen, J. S.; Neitz, J.; Latimer, L. H.; Varghese, J.; Freedman, S.; Britton, T. C.; Audia, J. E.; Reel, J. K.; Mabry, T. E.; Dressman, B. A.; Cwi, C. L.; Droste, J. J.; Henry, S. S.; McDaniel, S. L.; Scott, W. L.; Stucky, R. D.; Porter, W. J. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds. International Patent Application WO 98/28268, 1998.